BPC-157: What the Evidence Actually Shows

Search "BPC-157" and the claims stack up fast: gut healing, tendon and ligament repair, faster recovery from almost any soft-tissue injury. What's harder to find in that same search is a plain statement of where those claims actually come from. This article traces them to their source — the published animal studies, the small handful of human pilot studies, and the current regulatory record — rather than repeating what a seller's product page says the research shows.

The short version, stated up front rather than buried at the end: a 2025 systematic review that searched PubMed, Cochrane, and Embase from 1993 through mid-2024 found 36 total studies on BPC-157 and reported the split directly — "35 preclinical studies, 1 clinical study¹." A second, independent review reached the same conclusion from its own separate search: "Only three pilot studies have examined BPC-157 in humans²," and all three, it turns out, share the same lead investigator and the same single journal. That's the evidence base this article works from — not a hedge, the actual count.

What BPC-157 is, and its proposed mechanism

BPC-157 (body protection compound-157) is a synthetic 15-amino-acid peptide — sequence GEPPPGKPADDAGLV — described in the literature as a partial sequence of a larger protective compound identified in human gastric juice⁵. It has never been developed into an FDA-approved drug; it exists only as a research compound and, currently, an unregulated compounding-market product.

Mechanistically, the published animal and cell-culture literature converges on a few overlapping pathways rather than one single mechanism: activation of VEGFR2 and nitric-oxide synthesis through the Akt-eNOS axis (driving new blood-vessel growth), engagement of ERK1/2 signaling, increased growth-hormone receptor expression, and a reduction in inflammatory cytokines — proposed to jointly support angiogenesis, fibroblast activity, and tissue repair, particularly in poorly vascularized tissue like tendon²¹. A separate rat Achilles-tendon study gets more specific about the cellular mechanics: BPC-157 significantly increased tendon-fibroblast outgrowth from tendon explants, improved fibroblast survival under oxidative stress, and dose-dependently increased both fibroblast migration and the phosphorylation of FAK and paxillin — two proteins central to how a cell attaches to and moves across a wound surface³. That's a real, specific, dose-responsive cellular mechanism. It is also, worth stating plainly, a mechanism observed in cultured rat cells and tendon explants — not a measurement of a healed human tendon.

What the animal evidence actually shows

The animal literature behind BPC-157 is large, decades-old, and reasonably consistent in direction — which is exactly why it gets cited so heavily in marketing copy. It is also, per the systematic review's own count above, essentially the entire evidence base. Two representative findings, read directly from the source studies rather than a secondary paraphrase:

• •Gastric ulcers, rats. A 2004 study induced acute and chronic gastric ulcers in rats and treated them with BPC-157 by intramuscular or intragastric injection. At the highest intramuscular dose tested (800 ng/kg), the ulcer-inhibition ratio ranged from 59.9% to 65.6% across three separate ulcer-induction models — numerically better, in this same rat data, than the comparator drug famotidine, which ranged 34.3%-60.8% across the same three models. Continuous dosing also measurably accelerated rebuilding of the glandular epithelium in the chronic-ulcer model⁴. This is a real, dose-responsive, statistically significant finding — in rats, using an induced-injury model, with an outcome (visible ulcer area) that is straightforward to measure on a sacrificed animal in a way no equivalent human outcome measure could be taken as casually.
• •Tendon repair, rat cells. The FAK/paxillin mechanism study above is the clearest window into why BPC-157 shows up so often in tendon and ligament marketing specifically: it is one of relatively few peptides with a published, dose-responsive cellular mechanism for accelerating fibroblast migration in tendon tissue³. The systematic review adds that across the full preclinical literature it screened, BPC-157 "improved functional, structural, and biomechanical outcomes" in animal models of muscle, tendon, ligament, and bone injury, and reported no adverse effects across the organ systems those preclinical safety studies checked¹.

Two things are true of this animal data at once, and this article means both: it is real, peer-reviewed, and mechanistically coherent — not junk science. And it is animal data. Rat ulcer-inhibition ratios and cultured tendon-fibroblast migration rates are not the same claim as "heals gut and tendon injuries in people," and the review that assembled this exact literature does not make that leap either — its own conclusion calls the level of evidence "level IV and level V," the systematic-review field's lowest tiers, reserved for case series and expert opinion rather than controlled trials¹.

What the human evidence actually shows

This is the section most BPC-157 marketing skips, and it is short because the evidence itself is short. As of this review, exactly three published human studies exist, and all three share a detail worth stating directly because no secondary source repeats it: the same first author, Dr. Emil Lee, and the same single journal, Alternative Therapies in Health and Medicine, across every one of them.

• •Knee pain (2021). A retrospective chart review at one Florida clinic: 17 patients had received an intra-articular BPC-157 injection (12 alone, 4 combined with a second peptide) 6-12 months prior; 16 were reached by phone survey. Fourteen of 16 (87.5%) reported improvement. There was no control group, no blinding, no standardized pain-measurement tool, and the outcome was a phone-survey recollection of pain months after the fact, not a prospective, examiner-assessed measure⁶.
• •Interstitial cystitis (2024). A single-arm pilot at one clinic: 12 women who had not responded to standard pentosan-polysulfate therapy received one intravesical BPC-157 injection (10 mg) during cystoscopy. Ten of 12 reported complete symptom resolution; the other two reported partial relief. No control group. The study's own methods section states the peptide used was "manufactured by a 503A compounding pharmacy" — meaning even this small dataset describes one specific compounded batch, not a standardized reference product every seller's vial can be assumed to match⁷.
• •IV safety (2025). Two patients, ages 58 and 68, received escalating intravenous BPC-157 (10 mg, then 20 mg) at the same clinic. Bloodwork across cardiac, hepatic, renal, thyroid, and glucose markers showed no measurable change, and no side effects were reported⁸.

A separate biopharmaceutical review, searching independently, arrived at the same total: "fewer than 30 subjects across three uncontrolled pilot studies, none of which employed standardized pharmaceutical preparations⁵." Read plainly: the entire published human evidence base for BPC-157, across every claimed use, is two case series and one safety pilot, from one clinic, with a combined enrollment under 30 people, no placebo arm anywhere, and no blinding anywhere.

One more human data point exists, and it is not a completed study: a Phase 1 safety and pharmacokinetics trial (NCT02637284, sponsored by the Croatian firm PharmaCotherapia) enrolled 42 healthy volunteers starting in October 2015, with an estimated completion of March 2016. Its status on ClinicalTrials.gov today reads "UNKNOWN" — the registry's own designation for a trial whose sponsor never returned to confirm completion or post results, a decade past its target finish date. No results from this trial have ever been published. That is not proof the drug is unsafe; it is an unreported trial, which is a different, narrower fact, and this article states it as exactly that.

The one genuinely new development is a currently recruiting trial: NCT07437547, sponsored by Hudson Biotech, a randomized, double-blind, placebo-controlled Phase 2 study of BPC-157 for acute grade II hamstring muscle strain, which actually started enrollment in February 2026. Its co-primary endpoints — time to unrestricted return to sport, and MRI-measured injury volume at day 14 — are exactly the kind of controlled, objective outcome measures the human literature above lacks. It is the first controlled human trial of BPC-157 this review could locate. It has no results yet. Anyone citing this trial today can accurately say it exists and what it's designed to measure — not what it found, because it hasn't reported anything.

The current FDA and anti-doping status

BPC-157 has never had an FDA-approved product, application, or label. Its compounding status specifically has moved several times in the past three years, and moved again very recently: FDA placed it in Category 2 of its interim 503A bulk-substances list — substances presenting significant safety risks that should not be compounded — in September 2023. In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that Category 2 peptides would be reconsidered, and on April 15, 2026, BPC-157 was formally removed from Category 2 (via the original nominator withdrawing their nomination, not an FDA safety reversal). That removal did not add BPC-157 to the approved 503A Bulks List — it only took it off the do-not-compound list. On July 23, 2026, FDA's own Pharmacy Compounding Advisory Committee (PCAC) discussed BPC-157 specifically for inclusion on the 503A Bulks List, evaluated for the use of ulcerative colitis, and voted 8-6 with one abstention to recommend it. That vote is advisory, not a rule; formal notice-and-comment rulemaking has not started and could extend into 2027 or beyond. As of this writing, BPC-157 is not on a finalized, legally authorized 503A bulks list, and there is still no FDA-approved product of any kind.

Separately from FDA's compounding-status track, BPC-157 is explicitly named on the World Anti-Doping Agency's 2026 Prohibited List, in category S0 (Non-Approved Substances) — banned at all times, in and out of competition, for any tested athlete, with no path to a therapeutic use exemption because S0 substances are categorically ineligible for one.

What this means if you're considering a compounded BPC-157 product

Put the pieces together and the honest picture is this: a large, mechanistically coherent, and reasonably consistent animal literature; a human evidence base of three small, uncontrolled, single-clinic pilot studies from one research group, plus one unreported decade-old Phase 1 trial and one currently-recruiting Phase 2 trial with no results yet; and a compounding-legal status that is actively in motion rather than settled, with an advisory committee recommendation on the table but no finalized rule behind it.

None of that is a verdict on whether BPC-157 works in people — the honest answer is that the trials capable of answering that question either haven't been run yet or haven't reported. What it does mean, concretely, for anyone weighing a compounded BPC-157 product: the interstitial-cystitis pilot study above is a useful reminder that even the thin human data that exists was generated on one specific compounding pharmacy's preparation, not a standardized reference product every seller's vial can be assumed to match. A study finding — animal or the sparse human pilot data alike — describes what was in the syringe the researchers controlled and verified. It says nothing about the identity, purity, or concentration of a vial purchased from an unregulated seller under the same name. Our BPC-157 reconstitution calculator covers that distinction directly, and does the vial-to-syringe arithmetic without validating the product itself, because — as this review confirms independently — there is currently no FDA-approved product or agency-set dosing standard to validate it against.